Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

Biogen Lifts Outlook As Rare Disease And Alzheimer's Drug Sales Accelerate

Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the second quarter of 2025 adjusted earnings per share were $5.47, up 4% year over year, beating the analyst consensus of $4.06.

Benzinga

AbbVie Lifts Outlook, Eyes Parkinson's Assets As Next Growth Frontier

AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 billion. Sales increased 6.6% on a reported basis or 6.5% on an operational basis. The company reported adjusted earnings of $2.97, up 12.1% year over year and missing the consensus of $3.23.

Benzinga

Bristol Myers Cuts Earnings Outlook As Legacy Drugs Face Generic Erosion

Bristol Myers Squibb Co (NYSE:BMY) reported second-quarter 2025 revenues of $12.27 billion, beating the consensus of $11.31 billion, almost flat year over year.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Sanofi's Q2 Earnings Fall Short On Expectations Despite 21% Jump In Dupixent Sales

Sanofi SA (NASDAQ:SNY) reported second-quarter sales of $11.33 billion (€9.99 billion euros), narrowly missing the consensus of $11.53 billion.

Benzinga

Takeda Pharma Maintains Outlook Even As Vyvanse Generics Hit Sales

Takeda Pharmaceutical Company Limited (NYSE:TAK) posted a strong first-quarter performance for 2025 on Wednesday, with a net profit of 124.2 billion Japanese yen (approximately $834.08 million), reflecting a notable 30.4% year-over-year increase.

Benzinga

Quantum BioPharma Shares' Rollercoaster Day: What's Going On?

Shares of Quantum BioPharma Ltd (NASDAQ:QNTM) started Wednesday with a surge before dropping, then heading back up slightly, despite a lack of company-specific news for the session. The biopharmaceutical company last week announced it had purchased 2,000 shares of GameStop Corp (NYSE:GME) as a strategic investment for its balance sheet.…

Benzinga

Ionis Posts Surprise Q2 Profit, Double Revenues On Stronger Sales From Newly Approved Genetic Disease Drug

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) reported second-quarter adjusted earnings of 85 cents on Wednesday. The company reported an adjusted loss of $35 million a year ago.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Teva Pharma Boosts Outlook For Key Innovative Drugs Austedo, Ajovy, Uzedy

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) reported its second-quarter 2025 financial results on Wednesday, reflecting a mixed performance amid continued shifts in its portfolio strategy.

Benzinga

Novo Nordisk Stock Hits New 52-Week Low Amid Profit Warning: What Investors Need To Know

Shares of Novo Nordisk A/S (NYSE:NVO) are trading lower Wednesday morning, extending a dramatic sell-off from Tuesday’s session. Here’s what investors need to know.

Benzinga

GSK Lifts Outlook As Specialty Medicines, Vaccines Fuel Growth

British pharmaceutical giant GSK Plc (NYSE:GSK) shares rose on Wednesday after reporting second-quarter results that surpassed analyst expectations and led the company to raise its full-year 2025 guidance.

Benzinga

Novo Nordisk Charts Signal Weakness Amid Wegovy Warning, Expert Says 'Could've Played Out VERY Differently If They Had Embraced $HIMS'

Weight-loss drugmaker Novo Nordisk A/S (NYSE:NVO)’s technical chart is displaying a largely bearish trend amid a profit warning issued by the company tied to its blockbuster obesity drug Wegovy. However, this expert believes that the Danish pharmaceutical giant could have avoided some trouble if it hadn’t ended its partnership with…

Benzinga

UnitedHealth Stock Drags on Dow: Stock Market Today

Corporate earnings have dominated Wall Street's attention this week, but that changes on Wednesday.

Kiplinger

Generic Revlimid Fades, But Teva's Broader Generics Outlook Remains Strong

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) will release its second-quarter 2025 financial results tomorrow, July 30.

Benzinga

FDA Lifts Safety Hold On Sarepta's Muscular Dystrophy Gene Therapy—Wall Street Cheers

As gene therapies continue to evolve as a promising frontier in medical treatment, regulatory scrutiny intensifies following safety concerns. Recent developments with Sarepta Therapeutics Inc (NASDAQ:SRPT) highlight the delicate balance between innovation and patient safety in the biopharmaceutical industry.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

Ministers take note: now is the moment to fight to keep AstraZeneca’s listing in London

One hopes cogs are turning in Westminster after Pascal Soriot’s affectionate talk of US at pharmaceutical giant’s half-year results

Benzinga

What's Going On With Eli Lilly Stock On Tuesday?

Eli Lilly and Co. (NYSE:LLY) stock is trading lower on Tuesday after its weight loss drug rival, Novo Nordisk A/S (NYSE:NVO), trimmed its 2025 financial outlook.

The Independent UK

US health officials crack down on kratom-related products after complaints from supplement industry

U.S. health officials are cracking down on an opioid-like ingredient being added to drinks, supplements and other products

Benzinga

Incyte Surges Past Expectations With Strong Q2, Boosts Guidance On Jakafi Demand

Incyte Corporation (NASDAQ:INCY) reported on Tuesday that its second-quarter revenue was $1.22 billion, up 16% year over year. The company beat the consensus of $1.15 billion.

Get all your
news in one place.

100’s of premium titles.
One news app.

International Business Times

Novo Nordisk Cuts Earning Forecasts Again, Names New CEO

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, on Tuesday lowered its earning forecasts again as it unveiled a new chief executive to tackle "recent market challenges".

The Guardian - UK

AstraZeneca chief executive hails ‘vital importance of US’ as Trump tariffs loom

Pascal Soriot refuses to be drawn, however, on reports AZ could move its main stock market listing across the Atlantic

Benzinga

Merck CEO Sees Minimal EU Tariffs Impact, Warns Of Gardasil Challenges

Merck Co. Inc. (NYSE:MRK) shares fell over 6% in early trading Tuesday after the pharmaceutical giant reported a mixed second-quarter earnings picture, with adjusted earnings surpassing analyst consensus but overall sales experiencing a slight year-over-year decline and missing revenue expectations.

Benzinga

Novo Nordisk Implodes After Wegovy Warning—Is The Weight-Loss Bubble Bursting?

Novo Nordisk A/S (NYSE:NVO) suffered its worst trading session on record Tuesday, plunging as much as 25% in European markets after issuing a surprise profit warning tied to its blockbuster obesity drug Wegovy and appointing a new CEO.

Benzinga

AstraZeneca Q2 Sales Beat Estimates On Strong Cancer Drugs Revenues, Reaffirms 2025 Outlook

AstraZeneca Plc (NASDAQ:AZN) on Tuesday reported second-quarter 2025 sales of $14.46 billion, up 12% year over year (+11% at constant currency), marginally beating the consensus of $14.07 billion, driven by double-digit growth in oncology and biopharmaceuticals.

Benzinga

Drug Prices To Get 'More Expensive' Under Trump's EU Trade Deal As Pharma Faces Billions In Added Costs: Report

The pharmaceutical industry could face a significant financial hit due to the new trade deal between the U.S. and the European Union (EU), potentially leading to increased drug prices and restricted access.

The Guardian - UK

Trump’s 15% tariff on medicines will harm patients, say EU drugmakers

Trade group says levy will reduce access, disrupt supply chains and cut R&D

1 … 16 17 18 19

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.